Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Tempus and Takeda Expand Partnership to Enhance Cancer Drug Development with Real-World Data

NextEdge Admin

27 Sep 2024

1 min 38 sec

Tempus has expanded its collaboration with Takeda to enhance oncology research and development using real-world data. As part of the new agreement, Takeda will leverage Tempus' multimodal datasets and biological modeling to advance its cancer therapeutics pipeline. Researchers from Takeda will access de-identified patient records through Tempus' Lens analytics platform, utilizing AI-powered tools to accelerate drug development insights.

Takeda's oncology pipeline includes antibody-drug conjugates, small molecules, bispecific antibodies, and gamma delta T-cell therapies. The two companies are also collaborating on a multiphase biological modeling project using a large repository of patient-derived tumor organoids. By genetically linking these organoid models to Tempus' multimodal dataset through DNA sequencing assays, the partnership aims to improve predictions of drug efficacy.

Currently, Tempus and Takeda are evaluating a panel of 60 organoids across 10 cancer types to test preclinical drug candidates. Tempus COO Ryan Fukushima highlighted the promising results of the collaboration, noting that it could accelerate Takeda’s oncology pipeline and contribute to the development of next-generation cancer treatments.